drugset
drugset / Trial / NCT01890655

Extension Study of MT-1303

NCT01890655 ↗

Phase 2 Completed 367 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing remitting multiple sclerosis (RRMS).

Timeline

Start
2013-08
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject amiselimod Small molecule — —

Indications

relapsing-remitting multiple sclerosis